EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions

Leonie Bogaard, Kayan Tsoi, Bas van de Steeg, Esther F A Brandon, Lisanne Geers, Margreet van Herwaarden, Frank Jansman, Dominique Maas, Margje Monster-Simons, David S Y Ong, Sander D Borgsteede

Frontiers in Pharmacology · 30.09.2024 · 15

DOI: 10.3389/fphar.2024.1412692 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.09.2024. Verfasst von Leonie Bogaard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department Clinical Decision Support, Health Base Foundation, Houten, Netherlands. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug-drug interactions (DDIs) may influence the effectiveness and safety of medication treatment, which may require additional monitoring, dose adjustment or avoidance of certain drugs. DDIs involving P-glycoprotein (P-gp) affect many drugs, but current official product information is often insufficient to guide the management of these DDIs in clinical practice. The aim of this paper is to describe a protocol to assess DDIs involving P-gp and to develop and implement practice recommendations for clinically relevant P-gp-mediated DDIs that affect clinical outcomes through changes in systemic drug exposure.

Methods

A combined literature review and expert opinion approach will be used according to the following seven steps: set up an expert panel (step 1), establish core concepts and definitions (step 2), select potential P-gp-modulators (i.e., P-gp-inducers and -inhibitors) and P-gp-substrates to be evaluated (step 3), select and extract evidence-based data, and present findings in standardized assessment reports (step 4), discuss and adopt classifications and practice recommendations with the expert panel (step 5), publish and integrate information and alerts in clinical decision support systems (CDSS) (step 6), (re)assessments of DDIs and potential new DDIs when new information is available or when initiated by healthcare providers (step 7). Anticipated results The expert panel will classify potential P-gp-modulators and -substrates as clinically relevant P-gp-inducer, -inhibitor and/or -substrate and draw conclusions about which combinations of classified modulators and substrates will lead to clinically relevant DDIs. This may include the extrapolation of conclusions for DDIs where limited or no data are available, based on the pharmacological characteristics of these drugs. For (potential) DDIs that are considered to be clinically relevant, practice recommendations will be developed.

Discussion

This protocol describes a standardized, evidence- and expert opinion-based assessment of P-gp-mediated DDIs that affect clinical outcomes. This approach will generate alerts with practice recommendations for clinically relevant DDIs and transparent rationales for DDIs that are considered to be irrelevant. These recommendations will improve individual patient care by supporting healthcare professionals to make consistent decisions on how to manage P-gp mediated DDIs.

Schlagwörter

Stichwörter der Autor:innen

P-glycoproteinclinical decision supportdrug-drug interactionexpert opinionliterature reviewpractice recommendationsstudy protocol

Autor:innen und Institutionen

  • Department Clinical Decision Support, Health Base Foundation, Houten, Netherlands.
  • Department of Clinical Pharmacy, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
  • Dutch Medicines Evaluation Board, Utrecht, Netherlands.
  • Department of Clinical Pharmacy, Rijnstate Hospital, Arnhem, Netherlands.
  • Community Pharmacy Groesbeek, Groesbeek, Netherlands.
  • Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, Netherlands.

Zitieren

APA

Bogaard, L., Tsoi, K., van de Steeg, B., Brandon, E. F. A., Geers, L., van Herwaarden, M., Jansman, F., Maas, D., Monster-Simons, M., Ong, D. S. Y., & Borgsteede, S. D. (2024). A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1412692

Vancouver

Bogaard L, Tsoi K, van de Steeg B, Brandon EFA, Geers L, van Herwaarden M, et al. A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1412692

BibTeX
@article{Bogaard2024,
  author = {Bogaard, Leonie and Tsoi, Kayan and van de Steeg, Bas and Brandon, Esther F A and Geers, Lisanne and van Herwaarden, Margreet and Jansman, Frank and Maas, Dominique and Monster-Simons, Margje and Ong, David S Y and Borgsteede, Sander D},
  title = {A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1412692}
}
Kostenlos starten →